Research proves 'gender-bending' chemicals affect reproduction

October 26, 2010
New research has provided the first evidence that 'gender bending' chemicals which find their way from human products into rivers and oceans can have a significant impact on the ability of fish to breed in UK Rivers.

The findings from the four year study, led by the universities of Exeter and Brunel, has important implications for understanding the impacts of these chemicals on ecosystem health and possibly on humans.

Endocrine disrupting chemicals (EDCs) disrupt the ways that hormones work in the bodies of vertebrates (animals with backbones), including humans.
They can be found in everything from female contraceptive drugs and hormone replacement therapy pills, to washing up liquid, with the most well studied EDCs being those that mimic oestrogen (female hormone).

EDCs have been seeping into rivers through the sewage system for decades and have an observed effect on fish, altering male biology to make them more female – hence the 'gender bending' reputation of these chemicals.
Until now, there has been no solid evidence to show the long-term impact of this effect on fish in the wild - but the new research focusing on wild roach in two UK rivers (Bourne and Arun) has provided new evidence.

Two large-scale breeding studies assessed the ability of fish to breed by using a genetic technique (DNA microsatellites) to match offspring produced to their parents.
It was found that intersex fish – those that had their sexuality compromised by EDCs and which contain both male (sperm) and female (eggs) sex cells – had their reproductive performance reduced by up to 76%.

READ MORE

From the Independent


Female sexual dysfunction 'was invented by drugs industry' By Jeremy Laurance, Health Editor


Female sexual dysfunction – which is claimed to affect up to two thirds of women – is a disorder invented by the pharmaceutical industry to build global markets for drugs to treat it, it is claimed today.

Drug companies have invested millions in the search for a female equivalent of Viagra, so far without success. But while doing so they have stoked demand by creating a buzz around the disorder they have created, according to Ray Moynihan, a lecturer at the University of Newcastle in Australia.

Corporate employees worked with medical opinion leaders, ran surveys aimed at portraying the problem as widespread and helped create the diagnostic instruments to persuade women that their sexual difficulties deserved a medical label. But sex problems in women are far more complex than they are in men, encompassing lack of desire, lack of arousal and lack of orgasm and the drug industry's narrow focus is failing them.


READ MORE